Tailored drug combo tested for tough head and neck cancers
NCT ID NCT04326257
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested a personalized approach for people with advanced head and neck cancer that had stopped responding to prior immunotherapy. Researchers used genetic testing to choose which drug to add to nivolumab—either relatlimab or ipilimumab. The study enrolled 20 participants and measured how many had their tumors shrink significantly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nivolumab combined with either Relatlimab or Ipilimumab
What this could lead to
If successful, this approach could offer a new treatment option for patients with head and neck cancer that has stopped responding to standard immunotherapy.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The treatment may cause significant side effects and may not shrink tumors in most patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States